MX364560B - Proceso de microencapsulacion y producto. - Google Patents

Proceso de microencapsulacion y producto.

Info

Publication number
MX364560B
MX364560B MX2013003074A MX2013003074A MX364560B MX 364560 B MX364560 B MX 364560B MX 2013003074 A MX2013003074 A MX 2013003074A MX 2013003074 A MX2013003074 A MX 2013003074A MX 364560 B MX364560 B MX 364560B
Authority
MX
Mexico
Prior art keywords
core material
polymeric coating
minutes
product
composition
Prior art date
Application number
MX2013003074A
Other languages
English (en)
Other versions
MX2013003074A (es
Inventor
W Propst Cecil
Goll Diane
Original Assignee
Spi Pharma Inc Star
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Spi Pharma Inc Star filed Critical Spi Pharma Inc Star
Publication of MX2013003074A publication Critical patent/MX2013003074A/es
Publication of MX364560B publication Critical patent/MX364560B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/501—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5052—Proteins, e.g. albumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5052—Proteins, e.g. albumin
    • A61K9/5057—Gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)

Abstract

Se describe una composición que comprende un material de núcleo, que tiene un valor de sabor y un revestimiento polimérico. El revestimiento polimérico sustancialmente rodea el material de núcleo y comprende un polímero catiónico y opcionalmente un polímero aniónico. El revestimiento polimérico tiene un espesor uniforme que varía desde 2 um a 20 um. La composición proporciona la liberación de una porción del material de núcleo que es enmascarado de sabor durante un período de tiempo que varía desde 0.5 minutos a 2minutos en la cavidad oral y proporciona una liberación modificada del material de núcleo remanente en un tracto gastrointestinal.
MX2013003074A 2010-09-20 2011-09-20 Proceso de microencapsulacion y producto. MX364560B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38435110P 2010-09-20 2010-09-20
PCT/US2011/052406 WO2012040234A1 (en) 2010-09-20 2011-09-20 Microencapsulation process and product

Publications (2)

Publication Number Publication Date
MX2013003074A MX2013003074A (es) 2014-03-31
MX364560B true MX364560B (es) 2019-05-02

Family

ID=45874133

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013003074A MX364560B (es) 2010-09-20 2011-09-20 Proceso de microencapsulacion y producto.

Country Status (12)

Country Link
US (3) US10561621B2 (es)
EP (1) EP2629913B1 (es)
JP (2) JP6173912B2 (es)
KR (1) KR101869114B1 (es)
CN (1) CN103619514B (es)
AU (1) AU2011305572B2 (es)
BR (1) BR112013006381B1 (es)
CA (1) CA2821504C (es)
ES (1) ES2833075T3 (es)
MX (1) MX364560B (es)
WO (1) WO2012040234A1 (es)
ZA (1) ZA201302396B (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2734621B1 (en) 2011-07-22 2019-09-04 President and Fellows of Harvard College Evaluation and improvement of nuclease cleavage specificity
MX359554B (es) 2012-04-25 2018-10-02 Spi Pharma Inc Microesferas cristalinas y proceso para fabricacion de las mismas.
US9163284B2 (en) 2013-08-09 2015-10-20 President And Fellows Of Harvard College Methods for identifying a target site of a Cas9 nuclease
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US9322037B2 (en) 2013-09-06 2016-04-26 President And Fellows Of Harvard College Cas9-FokI fusion proteins and uses thereof
US9340800B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College Extended DNA-sensing GRNAS
US9526784B2 (en) 2013-09-06 2016-12-27 President And Fellows Of Harvard College Delivery system for functional nucleases
WO2016070129A1 (en) 2014-10-30 2016-05-06 President And Fellows Of Harvard College Delivery of negatively charged proteins using cationic lipids
JP2016536021A (ja) 2013-11-07 2016-11-24 エディタス・メディシン，インコーポレイテッド ＣＲＩＳＰＲ関連方法および支配ｇＲＮＡのある組成物
US20150165054A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting caspase-9 point mutations
CA2956224A1 (en) 2014-07-30 2016-02-11 President And Fellows Of Harvard College Cas9 proteins including ligand-dependent inteins
BR112017005574A2 (pt) * 2014-09-19 2017-12-12 Procter & Gamble formas de dosagem de liberação pulsada de fenilefrina
US9816080B2 (en) 2014-10-31 2017-11-14 President And Fellows Of Harvard College Delivery of CAS9 via ARRDC1-mediated microvesicles (ARMMs)
CN104549084B (zh) * 2014-12-04 2016-06-22 浙江工业大学 复合微胶囊壁材及微胶囊和制备方法
US9656233B2 (en) 2015-01-16 2017-05-23 Encapsys, Llc Reversible microcapsule filter cake
EP4434589A3 (en) 2015-10-23 2025-05-14 President and Fellows of Harvard College Evolved cas9 proteins for gene editing
US20190290182A1 (en) * 2016-07-11 2019-09-26 Ranvier Health Limited Method of diagnostic relevance based on taste recognition
JP7231935B2 (ja) 2016-08-03 2023-03-08 プレジデント アンド フェローズ オブ ハーバード カレッジ アデノシン核酸塩基編集因子およびそれらの使用
US11661590B2 (en) 2016-08-09 2023-05-30 President And Fellows Of Harvard College Programmable CAS9-recombinase fusion proteins and uses thereof
WO2018039438A1 (en) 2016-08-24 2018-03-01 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
AU2017342543B2 (en) 2016-10-14 2024-06-27 President And Fellows Of Harvard College AAV delivery of nucleobase editors
WO2018119359A1 (en) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Editing of ccr5 receptor gene to protect against hiv infection
CN110662556A (zh) 2017-03-09 2020-01-07 哈佛大学的校长及成员们 癌症疫苗
US11898179B2 (en) 2017-03-09 2024-02-13 President And Fellows Of Harvard College Suppression of pain by gene editing
JP2020510439A (ja) 2017-03-10 2020-04-09 プレジデント アンド フェローズ オブ ハーバード カレッジ シトシンからグアニンへの塩基編集因子
WO2018176009A1 (en) 2017-03-23 2018-09-27 President And Fellows Of Harvard College Nucleobase editors comprising nucleic acid programmable dna binding proteins
US11560566B2 (en) 2017-05-12 2023-01-24 President And Fellows Of Harvard College Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
US11732274B2 (en) 2017-07-28 2023-08-22 President And Fellows Of Harvard College Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE)
WO2019139645A2 (en) 2017-08-30 2019-07-18 President And Fellows Of Harvard College High efficiency base editors comprising gam
KR20200121782A (ko) 2017-10-16 2020-10-26 더 브로드 인스티튜트, 인코퍼레이티드 아데노신 염기 편집제의 용도
JP6955113B2 (ja) * 2017-12-08 2021-10-27 チェングアン バイオテック グループ カンパニー リミテッド リコピンマイクロカプセル粉末およびその製造方法
US12406749B2 (en) 2017-12-15 2025-09-02 The Broad Institute, Inc. Systems and methods for predicting repair outcomes in genetic engineering
US12157760B2 (en) 2018-05-23 2024-12-03 The Broad Institute, Inc. Base editors and uses thereof
US12522807B2 (en) 2018-07-09 2026-01-13 The Broad Institute, Inc. RNA programmable epigenetic RNA modifiers and uses thereof
CN113453702A (zh) 2018-09-28 2021-09-28 哈佛大学的校长及成员们 细胞重编程以逆转衰老并促进组织和组织再生
WO2020092453A1 (en) 2018-10-29 2020-05-07 The Broad Institute, Inc. Nucleobase editors comprising geocas9 and uses thereof
WO2020154500A1 (en) 2019-01-23 2020-07-30 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
MX2021011426A (es) 2019-03-19 2022-03-11 Broad Inst Inc Metodos y composiciones para editar secuencias de nucleótidos.
WO2020195132A1 (ja) * 2019-03-28 2020-10-01 富士フイルム株式会社 香料マイクロカプセル、香料マイクロカプセル組成物、柔軟剤及び洗剤
WO2020214842A1 (en) 2019-04-17 2020-10-22 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
US12435330B2 (en) 2019-10-10 2025-10-07 The Broad Institute, Inc. Methods and compositions for prime editing RNA
US20230118840A1 (en) * 2020-04-13 2023-04-20 Lg Chem, Ltd. Superabsorbent Polymer and Method for Preparing the Same
WO2021226558A1 (en) 2020-05-08 2021-11-11 The Broad Institute, Inc. Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence
WO2022179967A1 (en) 2021-02-23 2022-09-01 Glaxosmithkline Intellectual Property (No.2) Limited Vadadustat for treating covid-19 in a hospitalized subject
WO2023196851A1 (en) 2022-04-06 2023-10-12 President And Fellows Of Harvard College Reversing aging of the central nervous system

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4515769A (en) 1981-12-01 1985-05-07 Borden, Inc. Encapsulated flavorant material, method for its preparation, and food and other compositions incorporating same
US4800087A (en) * 1986-11-24 1989-01-24 Mehta Atul M Taste-masked pharmaceutical compositions
JPS63258641A (ja) 1987-04-16 1988-10-26 Suntory Ltd マイクロカプセルの製造方法
EP0465238B1 (en) 1990-07-04 1994-04-06 SHIONOGI SEIYAKU KABUSHIKI KAISHA trading under the name of SHIONOGI & CO. LTD. Process for preparing noncohesive coating layer
US5599556A (en) * 1991-12-31 1997-02-04 Abbott Laboratories Prolamine coatings for taste masking
ZA945944B (en) * 1993-08-13 1996-02-08 Eurand America Inc Procedure for encapsulating nsaids
GB9506844D0 (en) * 1995-04-03 1995-05-24 Armitage Ian M Pharmaceutical microencapsulation
US5607697A (en) * 1995-06-07 1997-03-04 Cima Labs, Incorporated Taste masking microparticles for oral dosage forms
US6165512A (en) * 1998-10-30 2000-12-26 Fuisz Technologies Ltd. Dosage forms containing taste masked active agents
GB9923045D0 (en) 1999-09-29 1999-12-01 Novartis Ag New oral formulations
CN100438769C (zh) * 2001-05-15 2008-12-03 宝洁公司 糖果组合物
US6951655B2 (en) 2001-10-11 2005-10-04 Imi Biomed, Inc. Pro-micelle pharmaceutical compositions
US7118765B2 (en) 2001-12-17 2006-10-10 Spi Pharma, Inc. Co-processed carbohydrate system as a quick-dissolve matrix for solid dosage forms
US6974592B2 (en) * 2002-04-11 2005-12-13 Ocean Nutrition Canada Limited Encapsulated agglomeration of microcapsules and method for the preparation thereof
US7132895B2 (en) 2002-06-27 2006-11-07 Bridgeco Ag Digitally-controlled oscillator
NZ539777A (en) 2002-11-04 2008-02-29 Ocean Nutrition Canada Ltd Microcapsules having multiple shells and method for the preparation thereof
US20070092562A1 (en) 2003-10-28 2007-04-26 Spi Pharma, Inc. Product and process for increasing compactibility of carbohydrates
EP1677736A4 (en) 2003-10-28 2007-09-12 Spi Pharma Inc PRODUCT AND PROCESS FOR INCREASING COMPACTION ABILITY FOR CARBOHYDRATES
JP2005187416A (ja) 2003-12-26 2005-07-14 Lion Corp マイクロカプセル及びその製造方法
EP1817009A2 (en) 2004-11-24 2007-08-15 Spi Pharma, Inc. Orally disintegrating compositions
US20060251702A1 (en) * 2005-05-05 2006-11-09 Cook Biotech Incorporated Implantable materials and methods for inhibiting tissue adhesion formation
DE102005062270A1 (de) 2005-12-24 2007-06-28 Bayer Technology Services Gmbh Geschmacksmaskierung von Pulvern
CN101410175B (zh) 2006-04-04 2013-11-20 弗门尼舍有限公司 通过凝聚制备微胶囊的方法
JP5979697B2 (ja) * 2006-06-05 2016-08-24 ディーエスエム ニュートリショナル プロダクツ アーゲーＤＳＭ Ｎｕｔｒｉｔｉｏｎａｌ Ｐｒｏｄｕｃｔｓ ＡＧ 改善された殻を有するマイクロカプセル
US20080132535A1 (en) 2006-11-30 2008-06-05 Transcept Pharmaceuticals, Inc. Stabilized Zolpidem Pharmaceutical Compositions
WO2008109806A2 (en) 2007-03-08 2008-09-12 Massachusetts Institute Of Technology Electrostatic coating of particles for drug delivery
ES2588429T3 (es) 2009-03-09 2016-11-02 Spi Pharma, Inc. Excipientes y sistemas de excipientes de compresión directa altamente compactables y durables
WO2011046609A2 (en) * 2009-10-15 2011-04-21 Appleton Papers Inc. Encapsulation
CN102740895B (zh) 2009-12-23 2016-02-24 伊利诺伊大学董事会 纳米轭合物以及纳米轭合物配制品

Also Published As

Publication number Publication date
JP2017128587A (ja) 2017-07-27
KR101869114B1 (ko) 2018-06-19
KR20140026324A (ko) 2014-03-05
ES2833075T3 (es) 2021-06-14
JP6445063B2 (ja) 2018-12-26
CN103619514A (zh) 2014-03-05
CA2821504C (en) 2019-03-26
AU2011305572A1 (en) 2013-04-11
ZA201302396B (en) 2014-12-23
WO2012040234A1 (en) 2012-03-29
JP2013537241A (ja) 2013-09-30
BR112013006381B1 (pt) 2024-02-15
BR112013006381A2 (pt) 2017-10-31
AU2011305572B2 (en) 2016-08-04
CA2821504A1 (en) 2012-03-29
MX2013003074A (es) 2014-03-31
US20200170959A1 (en) 2020-06-04
EP2629913A4 (en) 2015-09-30
US20230330032A1 (en) 2023-10-19
US20140044793A1 (en) 2014-02-13
CN103619514B (zh) 2016-09-28
EP2629913A1 (en) 2013-08-28
JP6173912B2 (ja) 2017-08-02
EP2629913B1 (en) 2020-08-26
US11723877B2 (en) 2023-08-15
US10561621B2 (en) 2020-02-18

Similar Documents

Publication Publication Date Title
MX364560B (es) Proceso de microencapsulacion y producto.
PH12014501446A1 (en) Solid nicotine-comprising dosage form with reduced organoleptic disturbance
CL2012002475A1 (es) Composicion para el cuidado bucal que comprende una fuente de calcio, una fuente de fosfato, un agente espesante y un humectante portador; producto para el cuidado bucal; y metodo de blanqueamiento.
MY161603A (en) Aqueous oral care composition comprising xanthan gum, cellulose gum and carbomer
EP2279677A4 (en) AROMATIC MATERIAL FOR A CIGARETTE, MANUFACTURING METHOD AND CIGARETTE
AR070863A1 (es) Preparacion solida de desintegracion oral y metodo para suprimir la ruptura de los granulos finos durante la produccion de un comprimido
PH12013502192A1 (en) Antibodies against human angiopoietin 2
WO2012056111A3 (en) Drug delivery compositions
WO2011056748A3 (en) Oral compositions for treatment of dry mouth
WO2012040623A3 (en) Nanostructured gels capable of controlled release of encapsulated agents
CA2861995C (en) Oral product comprising a mouth-stable polymer matrix and fibers
CY1113024T1 (el) Σπειροκυκλικα παραγωγα κυκλοεξανιου για τη θεραπεια της εξαρτησης ουσιων
EP2474299A4 (en) COLORED CAPSULE COMPOSITION FOR COSMETICS, PRODUCTION METHOD FOR THE COSMETIC FABRIC WITH THE COMPOSITION
BR112012005319A2 (pt) método para produzir uma resina sequestrante de oxigênio, composição e método para produzir um artigo
UY33076A (es) Microcápsulas de fexofenadina y composiciones que las contienen
MY149028A (en) Nalmefene hydrochloride dihydrate
ATE537817T1 (de) Nanoteilchen-träger zur verabreichung von arzneimitteln und verfahren zu ihrer herstellung
CY1115725T1 (el) Ενωσεις, συνθεσεις και μεθοδοι για την θεραπευτικη αγωγη των βητα-αμυλοειδικων ασθενειων και συνουκλεϊνοπαθειων
EP2366741A4 (en) POLYORGANOSILOXANE COMPOSITION, HARDENING PRODUCT FROM THE COMPOSITION AND METHOD FOR PRODUCING THE COMPOSITION
CL2013001770A1 (es) Proceso para la fabricacion de productos autoclavado de fibrocemento; y producto autoclavado de fibrocemento.
ZA201508750B (en) Compounds of '3-(5-sustituted oxy-2,4-dinitro-phenyl)-2-oxo-propionic acid ester', process and applications thereof
IL213671A (en) Pharmaceutical preparations containing alglitazar, a process for their preparation and use for the preparation of medicines
EP2586846A4 (en) INJECTION MATERIAL, METHOD FOR PRODUCING AN INJECTION MATERIAL AND INJECTION METHOD
PH12016500693B1 (en) Slow-release solid oral compositions
UA103290C2 (ru) Фармацевтическая композиция ибупрофена для инъекции

Legal Events

Date Code Title Description
FG Grant or registration